Moderna Inc. has encountered supply challenges for its Covid-19 vaccine, resulting in lower-than-expected sales for the latest quarter and a reduced forecast of dose deliveries and sales for the full year.
The Cambridge, Mass., company cited the complexities of shipping its vaccine doses to more countries, compared with delivering the vaccine during the initial rollout in the U.S. and a handful of other countries.
